BDSX Biodesix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BDSX

Price (delayed)

$16.41

Market cap

$165.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4

Enterprise value

$211.92M

?
Relative Growth: Rel. Growth: 67
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 33

Biodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue ...

Highlights
Biodesix's quick ratio has soared by 50% from the previous quarter and by 27% YoY
The company's gross profit rose by 35% YoY and by 10% QoQ
The equity has declined by 17% year-on-year
BDSX's debt is up by 15% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.biodesix.com
Peers: NEO OPK

Key stats

What are the main financial stats of BDSX

BDSX stock price

How has the Biodesix stock price performed over time
Intraday
1.93%
1 week
2.63%
1 month
45.61%
1 year
177.2%
YTD
141.32%
QTD
13.17%

Financial performance

How have Biodesix's revenue and profit performed over time
Revenue
$96.1M
Gross profit
$78.88M
Operating income
-$24.94M
Net income
-$31.96M
Gross margin
82.1%
Net margin
-33.3%
The operating margin has increased by 41% year-on-year and by 17% since the previous quarter
BDSX's net margin is up by 39% YoY and by 16% QoQ
The company's gross profit rose by 35% YoY and by 10% QoQ
Biodesix's revenue has increased by 29% YoY and by 9% QoQ

Price vs fundamentals

How does BDSX's price correlate with its fundamentals

Growth

What is Biodesix's growth rate over time

Valuation

What is Biodesix stock price valuation
P/E
N/A
P/B
17.72
P/S
1.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.21
BDSX's EPS is up by 28% year-on-year and by 14% since the previous quarter
The equity has declined by 17% year-on-year
The price to sales (P/S) is 103% higher than the last 4 quarters average of 0.8 but 33% lower than the 5-year quarterly average of 2.4
Biodesix's revenue has increased by 29% YoY and by 9% QoQ

Efficiency

How efficient is Biodesix business performance
BDSX's ROS is up by 44% year-on-year and by 20% since the previous quarter
BDSX's ROIC is up by 33% YoY and by 15% QoQ
The ROE is down by 19% QoQ
BDSX's return on assets is up by 12% since the previous quarter and by 11% year-on-year

Dividends

What is BDSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BDSX.

Financial health

How did Biodesix financials performed over time
The company's total assets is 11% higher than its total liabilities
The company's current ratio has surged by 52% QoQ and by 27% YoY
Biodesix's quick ratio has soared by 50% from the previous quarter and by 27% YoY
The debt to equity has soared by 127% since the previous quarter and by 39% year-on-year
The equity has declined by 17% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.